Rheumatoid Arthritis

How are new vial strengths transforming infliximab reimbursement in Germany? Recent policy updates introduce greater dosing flexibility for this widely used biologic, with the goal of improving cost-effectiveness and supporting more tailored patient care. Discover the latest developments and their impact on market access. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #costeffectiveness

Can a small country lead a global biotech surge? 🌍🔬 Portugal’s biotech ecosystem is turning strong academic R&D into market-ready therapies, diagnostics, and partnerships — driven by strategic funding, supportive regulation, and international collaborations that are accelerating exports and clinical programs. Read the full article to see which companies, policies, and investment trends are powering Portugal’s global impact — and what it means for investors, founders, and health systems. #SyenzaNews #biotechnology #globalhealth #innovation #MarketAccess